2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab

By afschroeder • August 20, 2025

Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew KW, Daar ES, Glidden DV, Hardy EJ, Johnson S, Li JZ, MacBrayne C, Nakamura MM, Riley L, Shafer RW, Shoham S, Tebas P, Tien PC, Loveless J, Falck-Ytter Y, Morgan RL, Gandhi RT. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab. Clin Infect Dis. 2025 Aug 20:ciaf355. doi: 10.1093/cid/ciaf355. Epub ahead of print. PMID: 40831386.

Tags: covid-19, guideline, Harbor UCLA, Infectious Diseases, infliximab, monoclonal antibody, Publications, SARS-CoV-2

Related Posts

Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design

Plutzky J, Taub PR, Bhatt DL, Al Dhaybi O, Aroda VR, Basile JN, Bloch MJ, Budoff M, Busch RS, Buse JB, Cheung D, Christofides EA,[...]

Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation

Oshima A, Serruys PW, Garg S, McEvoy JW, Wood DA, Doenst T, Taggart DP, Puskas JD, Shajahan A, Sharif F, Miyashita K, Tobe A, Tsai[...]

Microbiome Signatures in Advanced Gastric Cancer: Emerging Biomarkers for Risk Stratification, Therapy Guidance, and Prognostic Insight

Kim KJ, Zhong H, Tai D, Shah P, Park D, Goes V, Li J, Jung C, Kim L, Guzman S, Brar G, Castillo D. Microbiome[...]